MedPath

ProViS (Prolift+M and Vita Sexualis) Study

Completed
Conditions
Pelvic Organ Prolapse
Registration Number
NCT01997996
Lead Sponsor
Dr. med. Tanja Hülder
Brief Summary

Transvaginal meshes (TVM) are indicated for the treatment of pelvic organ prolapse (POP) where surgical intervention is necessary. Due to a potential risk of de novo dyspareunia, TVM are mainly used in postmenopausal women and in case of recurrent POP. PROLIFT+M (Trademark) is based on a highly flexible material which is partially absorbable. We suggest that PROLIFT+M has less impact on the vita sexualis than conventional TVM and could also be used for the treatment of younger and/or sexually active women. This study observes women who are routinely treated with PROLIFT+M with regard to their sexual function before and after the surgery. The hypothesis is that there is no worsening in vita sexualis with PROLIFT+M.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
18
Inclusion Criteria
  • The patient understands the nature and content of the trial
  • POP ≥ stage II (according to the POP-Q system (18))
  • Sexual intercourse ≥ 2x/4 weeks
  • Written informed consent
  • Negative pregnancy test in women of childbearing potential
  • Women ≥ 18 years
Exclusion Criteria
  • Concomitant surgery at the inner genitalis (e.g. colporrhaphy, sacrocolpopexy, sacrospinous fixation, hysterectomy); concomitant suburethral slings and bulking agents are allowed
  • Unable to read or speak German
  • Women < 18 years
  • Women who are pregnant or breastfeeding or planning future pregnancies
  • Acute infection(s), e.g. untreated urogenital infections

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
vita sexualis7 to 1 day Preoperative vs. 12 months (+/- 1 month) Postoperative

No worsening in vita sexualis (decrease in total score Female Sexual Function Index (FSFI-d) of ≤ 3.3; max. score = 36) measured at 12 months (+/- 1 month) postoperatively as compared to the preoperative score.

Secondary Outcome Measures
NameTimeMethod
Assessment of pelvic floor function7 to 1 day Preoperative vs. 12 months (+/- 1 month) Postoperative

Assessment of pelvic floor function using the validated German pelvic floor questionnaire at 12 months (+/- 1 month) postoperatively compared to preoperative (Deutscher Beckenboden-Fragebogen, validated German Version of the Australian Pelvic Floor Questionnaire

Assessment of patient satisfaction12 months (+/- 1 month) Postoperative

Assessment of patient satisfaction at 12 months (+/- 1 month) postoperatively using the visual analogue scale (VAS), question regarding reoperation and patient global (PGI) question.VAS: On top of two scales, the question "How satisfied are you with the result of your operation?" is placed. (Facial expressions are put above the line to express satisfaction visually). In addition, the following two questions are asked: "Would you have the operation done again?" and "In the past 12 months how would you rate your condition as opposed to before your recent pelvic floor operation: much better/a little better/about the same/a little worse/much worse" (PGI question).

pain during sexual intercourse7 to 1 day Preoperative vs. 12 months (+/- 1 month) Postoperative

No worsening in pain during sexual intercourse (decrease in weighted pain subscore FSFI-d of ≤ 1; max score = 6) measured at 12 months (+/- 1 month) postoperatively compared to preoperative.

Assessment of recurrent POP (POP-Q ≥ stage II)3 months (12 weeks +/- 2) and 12 months (+/- 1 month) postoperatively

Assessment of recurrent POP (POP-Q ≥ stage II in the operated compartment(s)), mesh erosion/exposure; each measured 3 (12 +/- 2 weeks) and 12 months (+/- 1 month) postoperatively by clinical examination (Speculum, palpation, POP-Q)

Safetyuntil 12 months (+/- 1 month) postoperatively

Safety (documentation and assessment of medical device incidents; serious incidents and near incidents will be reported to the competent authorities)

Trial Locations

Locations (4)

Klinikum Augsburg

🇩🇪

Augsburg, Bayern, Germany

Universitätsklinikum des Saarlandes

🇩🇪

Homburg/Saar, Saarland, Germany

Kantonsspital St.Gallen

🇨🇭

St.Gallen, Switzerland

DRK Krankenhaus Chemnitz-Rabenstein

🇩🇪

Chemnitz, Sachsen, Germany

© Copyright 2025. All Rights Reserved by MedPath